Sign in to confirm you’re not a bot
This helps protect our community. Learn more

June 4, 2024 Meeting of the Psychopharmacologic Drugs Advisory Committee (PDAC)

U.S. Food and Drug Administration
183K subscribers
19K views Streamed 1 year ago
The Committee will discuss new drug application (NDA) 215455, for midomafetamine (MDMA), submitted by Lykos Therapeutics, for the proposed indication of treatment of post-traumatic stress disorder. The Committee will be asked to discuss the overall benefit-risk profile of the product, including the potential public health impact. ...more
...more
June 4, 2024 Meeting of the Psychopharmacologic Drugs Advisory Committee (PDAC)
The Committee will discuss new drug application (NDA) 215455, for midomafetamine (MDMA), submitted by Lykos Therapeutics, for the proposed indication of treatment of post-traumatic stress disorder. The Committee will be asked to discuss the overall benefit-risk profile of the product, including the potential public health impact.

Follow along using the transcript.

U.S. Food and Drug Administration

183K subscribers
Live chat replay was turned off for this video.